Generic Drugs - Global Strategic Business Report

The global market for Generic Drugs is estimated at US$430.2 Billion in 2023 and is projected to reach US$671.5 Billion by 2030, growing at a CAGR of 6.6% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the generic drugs market is driven by several factors. Firstly, the rising incidence of chronic diseases and an aging population increase the demand for various medications, many of which are available as generics. The expiration of patents on several high-revenue drugs opens the door for generic manufacturers to introduce cost-effective alternatives. Additionally, technological advancements in pharmaceutical manufacturing enhance the efficiency and cost-effectiveness of producing generic drugs. Regulatory initiatives aimed at speeding up the approval process for generics and biosimilars also play a crucial role in market expansion. Consumer behavior trends, such as increased trust in generic medications and a greater focus on reducing healthcare expenditures, further propel market growth. Lastly, emerging markets with growing healthcare needs and improving healthcare infrastructure present new opportunities for generic drug manufacturers. These factors collectively drive the robust growth and adoption of generic drugs globally.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Small-Molecule Generics segment, which is expected to reach US$538.8 Billion by 2030 with a CAGR of a 4.8%. The Biosimilars segment is also set to grow at 17.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $130.2 Billion in 2023, and China, forecasted to grow at an impressive 8.2% CAGR to reach $126.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Generic Drugs Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Generic Drugs Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Generic Drugs Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Abbott Laboratories, Apotex Inc., ASKA Pharmaceutical Co., Ltd., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 255 Featured):

• Abbott Laboratories
• Apotex Inc.
• ASKA Pharmaceutical Co., Ltd.
• Aspen Pharmacare Holdings Limited
• AstraZeneca Plc
• Baxter International Inc.
• Dr. Reddy’s Laboratories Limited`
• Eli Lilly and Company
• Endo International plc
• F. Hoffmann-La Roche AG
• Fresenius Kabi AG
• GSK plc
• H. Lundbeck A/S
• Incepta Pharmaceuticals Ltd.
• Lupin Ltd.
• Novo Nordisk A/S
• Sandoz International GmbH
• Sanofi-Aventis U.S. LLC
• STADA Arzneimittel AG
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.